Niagen Bioscience Inc. (NAGE) exhibits 64.3% gross margins and 16.8% return on invested capital within Health Care (Medicinal Chemicals and Botanical Products), balanced against a 12.2x enterprise multiple and 4.8% implied options volatility.
Sustained 64.3% gross profitability converts into 12.6% operating margin and 16.8% ROIC, outpacing sector cost of capital.
ROIC: 16.8% // GM: 64.3%YoY revenue trajectory of +29.9% paired with 6.83% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +29.9% // FCF YLD: 6.83%Altman Z-Score of 4.40 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 4.40 // F-SCORE: 7/9Trading at 11.4x trailing P/E (9.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 11.4x // EV/EBITDA: 12.2xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $2.50 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medicinal Chemicals and Botanical Products require continuous execution to defend 13.4% net margins.
NET MARGIN: 13.4% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NAGE & activate live FRED threshold breach alerts.